Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus

US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.

insulin word on checkered paper sheet- vector illustration - Vector

As attention on the need for cheaper insulin intensifies, Mylan NV has secured a patent victory that positions it to launch a follow-on version of

Sanofi's Lantus (insulin glargine), which is pending at FDA. The US Patent and Trademark Office's Patent Trial and Appeal...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics